The Medicines and Healthcare Products Regulatory Agency Trading Fund (Appropriation of Additional Assets and Liabilities) Order 2014

Made: 25th February 2014

Laid before the House of Commons: 3rd March 2014

Coming into force: 24th March 2014

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Citation, commencement and interpretation

1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Appropriation of additional assets and liabilities to the Fund

2

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Appointed day for adding to originating debt of the Fund

3

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

SCHEDULE — ASSETS AND LIABILITIES APPROPRIATED TO THE FUND

PART 1 — ASSETS

1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

3

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

4

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

PART 2 — LIABILITIES

5

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

6

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Signed

Signed by authority of the Secretary of State for Health.

Earl Howe — Parliamentary Under-Secretary of State, — Department of Health — 2014-02-18

We concur

Anne Milton — Sam Gyimah — Two of the Lords’ Commissioners of Her Majesty’s Treasury — 2014-02-25

Explanatory note

(This note is not part of the Order)

EXPLANATORY NOTE

The Medicines and Healthcare Products Regulatory Agency Trading Fund (‘the Fund’) was established with effect from 1st April 2003 under the Government Trading Funds Act 1973 by the Medicines and Healthcare Products Regulatory Agency Trading Fund Order 2003 (S.I. 2003/1076). The operations suitable to be financed by means of the MHRA Trading Fund were amended by the Medicines and Healthcare Products Regulatory Agency Trading Fund (Amendment) Order 2005 (S.I. 2005/2061).

This Order provides for additional Crown assets and liabilities to be appropriated to the fund in respect of the provision of biological substances services from 1st April 2013 and appoints the day by which additional originating debt is to be added to the fund.

An impact assessment has not been produced for this instrument as no, or no significant, impact on the private, public or voluntary sectors is foreseen.

Footnotes

[^f00001]: 1973 c.63.

[^f00002]: S.I. 2003/1076, amended by S.I. 2005/2061.

[^f00003]: Sections 1, 2(2), (4) and (7) of the 1973 Act were substituted by section 1(1) of the Government Trading Act 1990 (c. 30) (“the 1990 Act”). Section 6(1) of the 1973 Act was substituted by section 2(3) of the 1990 Act.

[^f00004]: 2012 c.7.

[^f00005]: 1973 c.63.

Editorial notes